Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

Home
/
update
/
details

Myriad Genetics and Personalis Enter Cross-Licensing Agreement for Tumor-Informed MRD Testing

NextEdge Admin

12 Jul 2024

2 min 51 sec

Precision Oncology,MRD,Whole genome,Tumor

Myriad Genetics, Inc. and Personalis, Inc. have announced a cross-licensing agreement for their respective patent estates concerning tumor-informed approaches for detecting minimal residual disease (MRD). This partnership ensures both companie’s freedom to operate in the growing MRD market, projected to reach $20 billion, and enhances patient access to MRD testing benefits.

MRD tests are blood-based diagnostics that allow for closer monitoring of therapeutic responses and earlier cancer recurrence detection compared to traditional methods like imaging. Myriad and Personalis are leading the way with genome-scale, tumor-informed approaches that offer ultra-sensitive MRD tests. These tests facilitate earlier detection and better therapy monitoring, aiming to establish MRD testing as a standard of care.

Paul J. Diaz, President and CEO of Myriad Genetics, stated, “Our collaboration with Personalis aims to redefine MRD testing standards, increasing market access and informing clinical decision-making for oncology patients. Myriad’s Precise MRD, a part of our Precise Oncology Solutions, is a testament to our commitment to comprehensive molecular diagnostic tools for oncology.”

Chris Hall, CEO of Personalis, added, “Personalis has demonstrated the exceptional performance of our NeXT Personal® whole-genome-based MRD platform across various cancer cohorts. We are thrilled to deepen our collaboration with Myriad and recognize the importance of our patent estates in advancing MRD testing.”

About Myriad Genetics Myriad Genetics is a leading company in genetic testing and precision medicine, offering tests that assess disease risk and progression, guiding treatment decisions across various medical specialties. For more information, visit www.myriad.com.

About Personalis, Inc. Personalis is transforming cancer management with personalized testing, from biopsy through the patient's life. Their assays provide advanced insights for early MRD and recurrence detection, targeted therapy selection, and enhanced biomarker strategies for drug development. Personalis is based in Fremont, California.